Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Allogene Therapeutics (Nasdaq: ALLO) closed an underwritten public offering on April 16, 2026, selling 87,500,000 shares at $2.00 per share and 12,700,000 additional shares from the underwriters' option, raising $200.4 million in aggregate gross proceeds before fees.
Allogene expects to use net proceeds for general corporate purposes, which may include clinical trial expenses, research and development, general and administrative costs, and capital expenditures. The offering was completed off a shelf registration declared effective April 25, 2024, and a final prospectus supplement was filed with the SEC.
Positive
- $200.4 million gross proceeds from the offering
- Provides cash for clinical trial and R&D expenses
- Offered under a shelf registration effective April 25, 2024
Negative
- Issued 100.2 million shares (including option exercise), likely dilutive to existing shareholders
- Net proceeds will be reduced by underwriting discounts, commissions, and offering expenses
Details
News Market Reaction – ALLO
On Apr 17, the first trading day after this news, ALLO closed 0.84% above the previous close.
Data tracked by StockTitan Argus for the Apr 17 session.
Key Figures
- Primary shares offered
- 87,500,000 shares
- Underwritten public offering of common stock
- Offering price
- $2.00 per share
- Price to the public in this offering
- Additional shares
- 12,700,000 shares
- Underwriters’ partially exercised option
- Gross proceeds
- $200.4 million
- Aggregate gross proceeds before fees and expenses
- Current price
- $2.17
- Pre-news trading level on 2026-04-16
- 52-week range
- $0.8621 – $4.46
- Low and high prior to this offering close
- Volume today
- 73,881,976 shares
- Roughly 4.81x 20-day average volume
- Effective date reference
- April 25, 2024
- SEC effectiveness date referenced for related registration
Previous Offering Reports
-
Pricing of 87.5M-share common stock offering at $2.00 per share.
-
Proposed $175M common stock sale with additional underwriter option.
-
Pricing of $110M common stock offering at $2.90 per share.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
underwritten public offering financial
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of 87,500,000 shares of its common stock at a price to the public of
Allogene expects to use the net proceeds from this offering for general corporate purposes, which may include clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures.
Goldman Sachs & Co. LLC, Jefferies and TD Cowen acted as joint bookrunners for the offering. Piper Sandler and William Blair also acted as joint bookrunners for the offering. Baird and Canaccord Genuity acted as lead managers for the offering. TPG Capital BD, LLC acted as co-manager for the offering.
The shares of common stock described above were offered by Allogene pursuant to a shelf registration statement filed by Allogene with the Securities and Exchange Commission (SEC) that was declared effective on April 25, 2024. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by telephone at (877) 821-7388, or by emailing prospectus_department@jefferies.com; or from TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as “may,” “expects,” “goal,” “intend,” “will,” “would,” “subject to” or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding Allogene’s expectations with respect to the use of proceeds from the offering. For such statements, Allogene claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Allogene’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, those factors disclosed in Allogene’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026, and other filings that Allogene may make from time to time with the SEC. These forward-looking statements represent Allogene’s judgment as of the time of this release. Allogene disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.